William J. John

5.9k total citations · 3 hit papers
84 papers, 4.5k citations indexed

About

William J. John is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, William J. John has authored 84 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in William J. John's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (28 papers) and Lung Cancer Diagnosis and Treatment (16 papers). William J. John is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (28 papers) and Lung Cancer Diagnosis and Treatment (16 papers). William J. John collaborates with scholars based in United States, Spain and Germany. William J. John's co-authors include Luis Paz‐Ares, Eckart Laack, Annamaria H. Zimmermann, Patrick Peterson, Carla Visseren‐Grul, Filippo de Marinis, Nadia Chouaki, Michael Thomas, Jean-Louis Pujol and Mircea Dediu and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

William J. John

82 papers receiving 4.4k citations

Hit Papers

Maintenance pemetrexed plus best supportive care versus p... 2009 2026 2014 2020 2009 2012 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    2009 832 citations Tudor–Eliade Ciuleanu, Eckart Laack et al. profile →
  2. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
    2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology profile →
  3. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William J. John United States 29 3.0k 2.9k 972 585 425 84 4.5k
Á. Artal Spain 20 3.2k 1.1× 2.5k 0.8× 878 0.9× 606 1.0× 320 0.8× 82 4.3k
Thomas Müller Germany 23 2.5k 0.8× 2.2k 0.8× 949 1.0× 409 0.7× 288 0.7× 55 4.2k
Emilio Esteban Spain 27 2.3k 0.8× 2.6k 0.9× 1.2k 1.3× 737 1.3× 478 1.1× 161 4.1k
William N. William United States 33 2.0k 0.7× 1.5k 0.5× 893 0.9× 559 1.0× 901 2.1× 109 4.0k
Michael S. Rabin United States 27 1.9k 0.6× 2.3k 0.8× 654 0.7× 419 0.7× 257 0.6× 86 3.2k
Scott A. Laurie Canada 36 4.3k 1.4× 3.3k 1.1× 1.2k 1.3× 685 1.2× 1.2k 2.8× 163 6.3k
Vanesa Gregorc Italy 33 2.2k 0.7× 2.0k 0.7× 1.1k 1.1× 477 0.8× 167 0.4× 136 3.4k
Anna Spreafico Canada 31 2.3k 0.8× 1.2k 0.4× 1.2k 1.3× 591 1.0× 377 0.9× 229 3.8k
Luís Manso Spain 22 1.9k 0.6× 1.6k 0.5× 710 0.7× 802 1.4× 276 0.6× 153 3.3k
Sun Min Lim South Korea 27 1.5k 0.5× 1.6k 0.6× 900 0.9× 521 0.9× 216 0.5× 132 2.8k

Countries citing papers authored by William J. John

Since Specialization
Citations

This map shows the geographic impact of William J. John's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William J. John with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William J. John more than expected).

Fields of papers citing papers by William J. John

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William J. John. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William J. John. The network helps show where William J. John may publish in the future.

Co-authorship network of co-authors of William J. John

This figure shows the co-authorship network connecting the top 25 collaborators of William J. John. A scholar is included among the top collaborators of William J. John based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William J. John. William J. John is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Edward S., Karen Kelly, Luis Paz‐Ares, et al.. (2018). Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study. Clinical Cancer Research. 24(22). 5543–5551. 17 indexed citations
2.
Ferrer, Irene, Jon Zugazagoitia, Stephan Herbertz, et al.. (2018). KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer. 124. 53–64. 229 indexed citations
3.
Goldman, Jonathan W., Mariano Provencio, Shadia I. Jalal, et al.. (2017). P3.02c-102 Safety and Tolerability of Abemaciclib Combined with LY3023414 or with Pembrolizumab in Patients with Stage IV NSCLC. Journal of Thoracic Oncology. 12(1). S1341–S1342. 2 indexed citations
4.
Mazières, Julien, Sara M. Tolaney, Luis Paz‐Ares, et al.. (2017). P2.06-012 Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S1076–S1077. 2 indexed citations
5.
Gilden, Daniel, Joanna Kubisiak, Gerhardt Pohl, et al.. (2016). Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients. Journal of Medical Economics. 20(2). 151–161. 13 indexed citations
6.
Zimmermann, Annamaria H., Tudor–Eliade Ciuleanu, Paul A. Bunn, et al.. (2016). Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 104. 45–51. 6 indexed citations
7.
8.
Gridelli, Cesare, Filippo de Marinis, Michael Thomas, et al.. (2014). Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study. Journal of Thoracic Oncology. 9(7). 991–997. 40 indexed citations
9.
Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2012). Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. The Lancet Oncology. 13(3). 247–255. 447 indexed citations breakdown →
10.
Gridelli, Cesare, Filippo de Marinis, Jean-Louis Pujol, et al.. (2012). Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(11). 1713–1721. 44 indexed citations
11.
John, William J., et al.. (2010). Values in Transition: The Chiricahua Apache from 1886-1914. American Indian Law Review. 35(1). 9. 1 indexed citations
12.
13.
Atkins, James N., Samuel A. Jacobs, H. Samuel Wieand, et al.. (2005). Pemetrexed/Oxaliplatin for First-Line Treatment of Patients with Advanced Colorectal Cancer: A Phase II Trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clinical Colorectal Cancer. 5(3). 181–187. 19 indexed citations
14.
Oettle, Helmut, Donald Richards, Rajesh Ramanathan, et al.. (2005). A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology. 16(10). 1639–1645. 245 indexed citations
15.
Fizazi, Karim, William J. John, & Nicholas J. Vogelzang. (2002). The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Seminars in Oncology. 29(1). 77–81. 16 indexed citations
16.
Regine, William F., William J. John, Patrick C. McGrath, William E. Strodel, & Mohammed Mohiuddin. (2000). The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery. 7(1). 53–57. 6 indexed citations
17.
Miller, Kathy D., Joel Picus, Charles D. Blanke, et al.. (2000). Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Annals of Oncology. 11(1). 101–104. 80 indexed citations
18.
John, William J., et al.. (1998). Continuous Venous Infusion 5-Fluorouracil and Interferon-α in Pancreatic Carcinoma. American Journal of Clinical Oncology. 21(2). 147–150. 14 indexed citations
19.
John, William J., et al.. (1997). Bonhoeffer for a new day : theology in a time of transition : papers presented at the seventh International Bonhoeffer Congress, Cape Town, 1996.
20.
Regine, William F., William J. John, & Mohammed Mohiuddin. (1997). Current and Emerging Treatments for Pancreatic Cancer. Drugs & Aging. 11(4). 285–295. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Á. Artal Breakdown of academic impact, for papers by Thomas Müller Breakdown of academic impact, for papers by Emilio Esteban Breakdown of academic impact, for papers by William N. William Breakdown of academic impact, for papers by Michael S. Rabin Breakdown of academic impact, for papers by Scott A. Laurie Breakdown of academic impact, for papers by Vanesa Gregorc Breakdown of academic impact, for papers by Anna Spreafico Breakdown of academic impact, for papers by Luís Manso Breakdown of academic impact, for papers by Sun Min Lim
Rankless by CCL
2026